Harmony Biosciences (HRMY) Projected to Post Quarterly Earnings on Thursday

Key Points

• Harmony Biosciences is scheduled to report Q1 2026 results before the market opens on May 7, 2026 at 8:30 AM ET, with analysts projecting $0.76 EPS and $228.4 million in revenue.
• In the prior quarter the company missed EPS ($0.38 reported vs. $0.84 expected) but delivered revenue up 21.1% year‑over‑year
• Harmony trades with a market cap of roughly $1.8 billion and a P/E of 11.46, while the Street’s consensus rating is "Hold" with a consensus price target of $42.67; institutional investors own about 86.2% of the stock and analysts remain mixed on the name.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of $0.76 per share and revenue of $228.4080 million for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.46). The business had revenue of $243.78 million during the quarter, compared to analysts' expectations of $240.04 million. Harmony Biosciences had a net margin of 18.29% and a return on equity of 19.86%. Harmony Biosciences's revenue was up 21.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.85 earnings per share. On average, analysts expect Harmony Biosciences to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Harmony Biosciences Price Performance

NASDAQ:HRMY opened at $31.05 on Thursday. The company has a current ratio of 3.60, a quick ratio of 3.58 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $1.80 billion, a P/E ratio of 11.46, a P/E/G ratio of 0.42 and a beta of 0.89. Harmony Biosciences has a 12 month low of $25.52 and a 12 month high of $40.87. The business's 50-day moving average is $28.83 and its 200 day moving average is $32.84.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HRMY. Mizuho set a $50.00 price objective on Harmony Biosciences in a research note on Thursday, February 19th. Wall Street Zen downgraded Harmony Biosciences from a "buy" rating to a "hold" rating in a research note on Saturday, February 28th. Bank of America reduced their price objective on Harmony Biosciences from $32.00 to $28.00 and set an "underperform" rating on the stock in a research note on Wednesday, February 25th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of Harmony Biosciences in a research note on Wednesday, February 25th. Finally, Deutsche Bank Aktiengesellschaft downgraded Harmony Biosciences from a "buy" rating to a "hold" rating and set a $31.00 price objective on the stock. in a research note on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $42.67.

Institutional Trading of Harmony Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of HRMY. Amundi increased its stake in Harmony Biosciences by 115.6% in the first quarter. Amundi now owns 39,668 shares of the company's stock worth $1,229,000 after purchasing an additional 21,266 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Harmony Biosciences by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company's stock worth $752,000 after purchasing an additional 984 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Harmony Biosciences in the 1st quarter worth $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Harmony Biosciences by 53.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company's stock worth $3,166,000 after purchasing an additional 33,058 shares in the last quarter. Finally, Cetera Investment Advisers increased its holdings in shares of Harmony Biosciences by 9.8% in the second quarter. Cetera Investment Advisers now owns 8,404 shares of the company's stock valued at $266,000 after purchasing an additional 748 shares during the period. Hedge funds and other institutional investors own 86.23% of the company's stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company's mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company's flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.